Allogene Therapeutics Inc (NASDAQ:ALLO) shares shot up 5.3% on Monday . The stock traded as high as $27.71 and last traded at $27.67, 249,653 shares traded hands during trading. A decline of 42% from the average session volume of 429,294 shares. The stock had previously closed at $26.27.
Several brokerages have weighed in on ALLO. Stifel Nicolaus began coverage on shares of Allogene Therapeutics in a research report on Wednesday, May 22nd. They set a “hold” rating and a $27.00 price target for the company. BTIG Research started coverage on shares of Allogene Therapeutics in a research report on Friday, August 9th. They issued a “buy” rating and a $37.00 target price for the company. Guggenheim started coverage on shares of Allogene Therapeutics in a research report on Thursday, May 30th. They issued a “neutral” rating for the company. Oppenheimer started coverage on shares of Allogene Therapeutics in a research report on Friday, May 3rd. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Zacks Investment Research cut shares of Allogene Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Allogene Therapeutics has an average rating of “Buy” and a consensus target price of $36.10.
The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.46 and a current ratio of 13.46. The company’s 50-day moving average price is $28.27 and its 200 day moving average price is $28.37. The stock has a market capitalization of $3.20 billion and a PE ratio of -4.11.
Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.06. Analysts expect that Allogene Therapeutics Inc will post -1.94 earnings per share for the current year.
In related news, insider Alison Moore sold 48,828 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $26.76, for a total value of $1,306,637.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 36.50% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in Allogene Therapeutics by 26.3% during the 1st quarter. FMR LLC now owns 6,200,543 shares of the company’s stock valued at $178,313,000 after purchasing an additional 1,289,556 shares in the last quarter. BlackRock Inc. increased its stake in Allogene Therapeutics by 58.3% during the 2nd quarter. BlackRock Inc. now owns 3,562,333 shares of the company’s stock valued at $95,650,000 after purchasing an additional 1,312,056 shares in the last quarter. Vanguard Group Inc. increased its stake in Allogene Therapeutics by 64.0% during the 2nd quarter. Vanguard Group Inc. now owns 3,443,180 shares of the company’s stock valued at $92,449,000 after purchasing an additional 1,343,459 shares in the last quarter. LLBH Private Wealth Management LLC increased its stake in Allogene Therapeutics by 652.8% during the 2nd quarter. LLBH Private Wealth Management LLC now owns 1,155,717 shares of the company’s stock valued at $31,031,000 after purchasing an additional 1,002,199 shares in the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in Allogene Therapeutics during the 2nd quarter valued at about $14,967,000. Institutional investors own 52.83% of the company’s stock.
Allogene Therapeutics Company Profile (NASDAQ:ALLO)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.